Ampio trials explore potential COVID-19 treatment

By Jenni Spinner

- Last updated on GMT

Ampio trials explore potential COVID-19 treatment

Related tags COVID-19 Coronavirus phase I Phase 3 Immunology Clinical trial

The immunology-focused company has launched clinical research exploring the potential of its Ampion drug to treat the virus behind the pandemic.

Ampio Pharmaceuticals, a US-based company offering a range of immunology-based therapies for inflammatory conditions, has launched a clinical trial to test Ampion (administered intravenously) to treat COVID-19. In addition, the company reports it plans to expand its Phase I trial testing an inhaled version of the drug to treat the virus.

Michael Macaluso, chair and CEO of Ampio Pharmaceuticals, said the approval and rollout of vaccines is a positive step, treatments still are very much needed.

"While the vaccine will hopefully help many people avoid the more serious complications of COVID-19, the rollout of vaccines will take time and is unlikely to ever reach 100% of the public​," he said. "We will no doubt continue to need treatments to provide the essential relief and improve outcomes for patients, and we are especially excited to begin the testing of Ampion for COVID-19 in an outpatient setting​."

According to the company, Ampion can be used to interrupt the hyper-active immune response known as cytokine storm, frequently associated with serious COVID-19 symptoms. A range of various drugs are being explored to treat this COVID-related phenomenon.

A global study (initiated in the US and Israel) has been launched, with the intent to focus on patient safety and drug efficacy, as measured by improvement in the course of the desease and patient outcomes for people with moderate to severe COVID-19. The IV treatment targets inflammation in the body, and the study is intended to assess the effect of Ampion IV treatment in both hospital settings and outpatient care.

Additionally, a US-based Phase I trial, exploring the viability of inhaled Ampion, is being expanded to additional hospitals; Ampio Pharmaceuticals reports that to date, no drug-related serious adverse events have been reported in the ongoing research. The company plans to increase enrollment as frontline workers receive the vaccines, with the goal to conclude enrollment in January.

In addition to clinical trials sponsored by pharmaceutical firms, the National Institutes of Health (NIH) launched a Phase III trial in October​, designed to examine the viability of using immune modulators to treat hospitalized COVID-19 patients. The research aims to determine if focusing on immune response in such a way can reduce the length and severity of the disease, and to cut down the need for use of ventilators.

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Related suppliers

Follow us


View more